Generalized anxiety disorder (GAD) is a neuropsychological disorder, under the class of anxiety disorders characterized by excessive and uncontrollable worrying for six or more months. GAD is a major hurdle for personal and social productivity and a financial burden on governmental health sectors; moreover, it is one of the common mental health problems in Saudi Arabia and globally with physical and psychological manifestations (e.g., muscle tension, sleeplessness, disoriented thoughts, etc.). Although, there is not a mono-factor’s direct causality of pathogenesis, there are multiple risk factors such as genetics, socioeconomic status, and life experiences that may contribute to the development of GAD. Nonetheless, the diagnosis is made using the criteria set by the diagnostic and statistical manual of mental disorders, 5th edition (DSM-5) or the international classification of diseases 11th revision (ICD-11), which covers the patient’s past medical history and present social and environmental setting. The management of GAD includes a combination of psychiatric interventions (e.g., cognitive behavioral therapy) and different medications (e.g., selective-serotonin reuptake inhibitors) requiring thorough investigations and deep discussions with the patient to rule out other psychiatric conditions and to reach an optimal level of healthcare, preventing further deterioration. This article addresses the etiology, epidemiology, pathophysiology, diagnosis, and management of GAD in Saudi Arabia to present an integrated and updated review.
References
[1]
Alahmadi, A. M. (2019). Prevalence of Anxiety among College and School Students in Saudi Arabia: A Systematic Review. Journal of Health Informatics in Developing Countries, 13, 1-15. https://www.jhidc.org/index.php/jhidc/article/view/237
[2]
Alamri, H. S., Algarni, A., Shehata, S. F. et al. (2021). Prevalence of Depression, Anxiety, and Stress among the General Population in Saudi Arabia during Covid-19 Pandemic. International Journal of Environmental Research and Public Health, 17, 9183. https://doi.org/10.3390/ijerph17249183
[3]
Alegría, A., Hasin, D., Nunes, E. et al. (2019). Comorbidity of Generalized Anxiety Disorder and Substance Use Disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Clinical Psychiatry, 71, 1187-1195. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951633
[4]
Aljurbua, F. I., Selaihem, A., Alomari, N. A., & Alrashoud, A. M. (2021). A Cross-Sectional Study on Generalized Anxiety Disorder and Its Socio-Demographic Correlates among the General Population in Saudi Arabia. Journal of Family Medicine and Primary Care, 10, 3644. https://doi.org/10.4103/jfmpc.jfmpc_847_21
[5]
Alyami, H. S., Naser, A. Y., Dahmash, E. Z. et al. (2019). Depression and Anxiety during 2019 Coronavirus Disease Pandemic in Saudi Arabia: A Cross-Sectional Study. International Journal of Clinical Practice. https://doi.org/10.1101/2020.05.09.20096677
[6]
Arul, A. S. (2016). Study of Life Events and Personality Dimensions in Generalized Anxiety Disorder. Journal of Clinical and Diagnostic Research: JCDR, 10, VC05-VC09. https://doi.org/10.7860/JCDR/2016/18123.7652
[7]
Baldwin, D. (2019). Generalized Anxiety Disorder in Adults: Epidemiology, Pathogenesis, Clinical Manifestations, Course, Assessment, and Diagnosis. UpToDate. https://www.uptodate.com/contents/generalized-anxiety-disorder-in-adults-epidemiology-pathogenesis-clinical-manifestations-course-assessment-and-diagnosis#H448541483
[8]
Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of Anxiety Disorders. Dialogues in Clinical Neuroscience, 19, 93-107. https://doi.org/10.31887/DCNS.2017.19.2/bbandelow
[9]
Berryhill, M. B. (2019). Video Conferencing Psychological Therapy and Anxiety: A Systematic Review. Family Practice, 36, 53-63.
[10]
Bystritsky, A. (2019). Uptodate. https://www.uptodate.com/contents/pharmacotherapy-for-generalized-anxiety-disorder-in-adults
[11]
Chand, S. P., Kuckel, D. P., & Huecker, M. R. (2022) Cognitive Behavior Therapy. StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK470241/
[12]
Craske, M. (2020). Approach to Treating Generalized Anxiety Disorder in Adults. UPTODATE.
[13]
Diekhof, E. K., Geier, K., Falkai, P., & Gruber, O. (2011). Fear Is Only as Deep as the Mind Allows: A Coordinate-Based Meta-Analysis of Neuroimaging Studies on the Regulation of Negative Affect. Neuroimage, 58, 275-285. https://doi.org/10.1016/j.neuroimage.2011.05.073
[14]
DSM-5 (2013). Generalized Anxiety Disorder. Diagnostic and Statistical Manual of Mental Disorders (5th ed., pp. 222-226). American Psychiatric Publishing.
[15]
Fioranelli, M., Bottaccioli, A. G., et al. (2018) Stress and Inflammation in Coronary Artery Disease: A Review Psycho-Neuro-Endocrine-Immunology-Based. Frontiers in Immunology, 9, 2031. https://doi.org/10.3389/fimmu.2018.02031
[16]
Firth, J. (2017). Can Smartphone Mental Health Interventions Reduce Symptoms of Anxiety? A Meta-Analysis of Randomized Controlled Trials. Journal of Affective Disorders, 218, 15-22. https://doi.org/10.1016/j.jad.2017.04.046
[17]
Francis, J. L. (2012). Life Stress and GAD. Depression and Anxiety, 29, 5. https://doi.org/10.1002/da.20919
[18]
Gale, C. (2020). Generalised Anxiety Disorder. https://bestpractice-bmj-com.sdl.idm.oclc.org/topics/en-gb/120
[19]
Gosschalk, M. G. (2017). Genetics of Generalized Anxiety Disorder and Related Traits. Dialogues in Clinical Neuroscience, 19, 159-168. https://doi.org/10.31887/DCNS.2017.19.2/kdomschke
[20]
Griebel, G., & Holsboer, F. (2012). Neuropeptide Receptor Ligands as Drugs for Psychiatric Diseases: The End of the Beginning? Nature Reviews Drug Discovery, 11, 462-478. https://doi.org/10.1038/nrd3702
[21]
Grillon, C., O’Connell, K., Lieberman, L. et al. (2017). Distinct Responses to Predictable and Unpredictable Threat in Anxiety Pathologies: Effect of Panic Attack. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2, 575-581. https://doi.org/10.1016/j.bpsc.2016.08.005
[22]
Hariri, A., Drabant, E., Munoz, K. et al. (2005). A Susceptibility Gene for Affective Disorders and the Response of the Human Amygdala. Archives of General Psychiatry, 62, 146. https://doi.org/10.1001/archpsyc.62.2.146
[23]
Hilbert, K., Lueken, U., & Beesdo-Baum, K. (2014). Neural Structures, Functioning and Connectivity in Generalized Anxiety Disorder and Interaction with Neuroendocrine Systems: A Systematic Review. Journal of Affective Disorders, 158, 114-126. https://doi.org/10.1016/j.jad.2014.01.022
[24]
Hoge, E. A., Ivkovic, A., & Fricchione, G. L. (2012). Generalized Anxiety Disorder: Diagnosis and Treatment. BMJ: British Medical Journal, 345, e7500. https://doi.org/10.1136/bmj.e7500
[25]
Hompes, T., Izzi, B., Gellens, E. et al. (2013). Investigating the Influence of Maternal Cortisol and Emotional State during Pregnancy on the DNA Methylation Status of the Glucocorticoid Receptor Gene (NR3C1) Promoter Region in Cord Blood. Journal of Psychiatric Research, 47, 880-891. https://doi.org/10.1016/j.jpsychires.2013.03.009
[26]
Ibrahim, N., Dania, A. K., Lamis, E. K. et al. (2013). Prevalence and Predictors of Anxiety and Depression among Female Medical Students in King Abdulaziz University, Jeddah, Saudi Arabia. Iranian Journal of Public Health, 42, 726.
Locke, A., Kirst, N., & Shultz, C. (2015). Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults. American Family Physician, 91, 617-624. https://www.aafp.org/afp/2015/0501/p617.html
[29]
Makovac, E., Meeten, F., Watson, D. R., et al. (2016) Alterations in Amygdala-Prefrontal Functional Connectivity Account for Excessive Worry and Autonomic Dysregulation in Generalized Anxiety Disorder. Biological Psychiatry, 80, 786-795. https://doi.org/10.1016/j.biopsych.2015.10.013
[30]
Mantella, R. C., Butters, M. A., Amico, J. A. et al. (2008). Salivary Cortisol Is Associated with Diagnosis and Severity of Late-Life Generalized Anxiety Disorder. Psychoneuroendocrinology, 33, 773-781. https://doi.org/10.1016/j.psyneuen.2008.03.002
[31]
Mathew, S. J., Amiel, J. M., Coplan, J. D. et al. (2005). Open-Label Trial of Riluzole in Generalized Anxiety Disorder. American Journal of Psychiatry, 162, 2379-2381. https://doi.org/10.1176/appi.ajp.162.12.2379
[32]
Mennin, D., Heimberg, R., & Jack, M. (2000). Comorbid Generalized Anxiety Disorder in Primary Social Phobia. Journal of Anxiety Disorders, 14, 325-343. https://doi.org/10.1016/S0887-6185(00)00026-8
[33]
Moller, E. L. (2016). Parenting Behaviors and Anxiety Meta-Analysis. Clinical Psychology Review.
Murphy, T. M., O’Donovan, A., et al. (2015) Anxiety is Associated with Higher Levels of Global DNA Methylation and Altered Expression of Epigenetic and Interleukin-6 Genes. Psychiatric Genetics, 25, 71-78. https://doi.org/10.1097/YPG.0000000000000055
[36]
Nemeroff, C. B. (2003). The Role of GABA in the Pathophysiology and Treatment of Anxiety Disorders. Psychopharmacology Bulletin, 37, 133-146.
[37]
Non, A. L., Binder, A. M., Kubzansky, L. D., & Michels, K. B. (2014) Genome-Wide DNA Methylation in Neonates Exposed to Maternal Depression, Anxiety, or SSRI Medication during Pregnancy. Epigenetics, 9, 964-972. https://doi.org/10.4161/epi.28853
[38]
Nutt, D. J. (2001). Neurobiological Mechanisms in Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 62, 22-28.
[39]
O’Donohue, W., & Fisher, J. (2012). Cognitive Behavior Therapy (pp. 86-88). Wiley.
[40]
Patriquin, M., & Mathew, S. (2017). The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress. Chronic Stress (Thousand Oaks), 1. https://doi.org/10.1177/2470547017703993
[41]
Pittenger, C., Coric, V., Banasr, M. et al. (2008). Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs, 22, 761-786. https://doi.org/10.2165/00023210-200822090-00004
[42]
Rakel, R., Rakel, D., & Ahmed, S. (2016). Textbook of Family Medicine (9th ed.). Elsevier/Saunders.
[43]
Ray, S., & Stowe, Z. N. (2014). The Use of Antidepressant Medication in Pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology, 28, 71-83. https://doi.org/10.1016/j.bpobgyn.2013.09.005
[44]
Ritchie, H., & Roser, M. (2022). Mental Health. Our World in Data. https://ourworldindata.org/mental-health#anxiety-disorders
[45]
Roy, A. K., Fudge, J. L., Kelly, C. et al. (2013). Intrinsic Functional Connectivity of Amygdala-Based Networks in Adolescent Generalized Anxiety Disorder. The Journal of the American Academy of Child & Adolescent Psychiatry, 52, 290-299.e2. https://doi.org/10.1016/j.jaac.2012.12.010
[46]
Sajdyk, T. J., Shekhar, A., & Gehlert, D. R. (2004). Interactions between NPY and CRF in the Amygdala to Regulate Emotionality. Neuropeptides, 38, 225-234. https://doi.org/10.1016/j.npep.2004.05.006
[47]
Samreen, S., Siddiqui, N. A., & Mothana, R. A. (2020). Prevalence of Anxiety and Associated Factors among Pharmacy Students in Saudi Arabia: A Cross-Sectional Study? BioMed Research International, 2020, Article ID: 2436538. https://doi.org/10.1155/2020/2436538
[48]
Strawn, J., Geracioti, L., Rajdev, N. et al. (2018). Pharmacotherapy for Generalized Anxiety Disorder in Adult and Pediatric Patients: An Evidence-Based Treatment Review. Expert Opinion on Pharmacotherapy, 19, 1057-1070. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340395
[49]
Turkistani, I., Nuqali, A., Badawi, M. et al. (2014). The Prevalence of Anxiety and Depression among End-Stage Renal Disease Patients on Hemodialysis in Saudi Arabia. Renal Failure, 36, 1510-1515. https://doi.org/10.3109/0886022X.2014.949761
[50]
Wang, H., Wong, P. T., Spiess, J., & Zhu, Y. Z. (2005). Cholecystokinin-2 (CCK2) Receptor-Mediated Anxiety-Like Behaviors in Rats. Neuroscience & Biobehavioral Reviews, 29, 1361-1373. https://doi.org/10.1016/j.neubiorev.2005.05.008
[51]
Wilkinson, A., Meares, K., & Freeston, M. (2011). CBT for Worry and Generalised Anxiety Disorder. Sage. https://doi.org/10.4135/9781446289105
[52]
Zbozinek, T., Rose, R., Wolitzky-Taylor, K. et al. (2012). Diagnostic Overlap of Generalized Anxiety Disorder and Major Depressive Disorder in a Primary Care Sample. Depress Anxiety, 29, 1065-1071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629816
[53]
Zhu, Z., Zhang, L., Jiang, J. et al. (2014). Comparison of Psychological Placebo and Waiting List Control Conditions in the Assessment of Cognitive Behavioral Therapy for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis. Shanghai Archives of Psychiatry, 26, 319-331.
